Lab Med Online.  2011 Jul;1(3):138-146.

Serial Determination of FLT3-ITD and NPM1 Mutations and Its Clinical Significance in Patients with MDS at Diagnosis and After Progression to AML with Myelodysplasia-related Changes

Affiliations
  • 1Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. hschi@amc.seoul.kr

Abstract

BACKGROUND
Accumulation of genetic aberrations in MDS is closely associated with progression to AML. FLT3-ITD is commonly found in AML and less frequently in MDS. FLT3-ITD in MDS is associated with a high risk of transformation to AML. Recently, significant interaction of NPM1 and FLT3-ITD was described in AML. This study was conducted to investigate the incidence and prognostic role of FLT3-ITD and NPM1 mutations (NPM1mt) on paired samples at diagnosis of MDS and AML.
METHODS
Patients who were diagnosed as MDS transforming to AML were included. FLT3-ITD was detected by PCR, and NPM1mt was confirmed by direct sequencing after screening for NPM by immunohistochemistry.
RESULTS
AML developed in 12.0% (43/357) of MDS patients. FLT3-ITD was detected in none of MDS and 14.7% (5/34) of AML. NPM1mt was detected in 2.4% (1/41) of MDS and 11.6% (5/43) of AML. One patient with type B NPM1mt at MDS transformed to type A NPM1mt at AML. FLT3-ITD positive AML showed a tendency of shorter survival and a significantly longer time to achieve complete remission than FLT3-ITD negative AML (P=0.007). Normal karyotype AML with FLT3-ITD showed shorter overall survival than that group of AML without FLT3-ITD (P=0.017).
CONCLUSIONS
MDS patients acquired FLT3-ITD during AML transformation, and FLT3-ITD positive AML, especially that with normal karyotype, predicted a poor outcome. NPM1mt was identified in both MDS and AML. NPM1mt was rarely found in MDS patients, and mostly was acquired after AML transformation. Clonal evolution of NPM1mt subtype was found in one patient during acute transformation.

Keyword

MDS; AML; Fms-like tyrosine kinase 3 (FLT3); Nucleophosmin (NPM)

MeSH Terms

Clonal Evolution
Humans
Incidence
Karyotype
Mass Screening
Polymerase Chain Reaction

Figure

  • Fig. 1. Results of NPMc+ and NPM1 exon 12 type B mutation in a patient with AML M2 transformed from RAEB1. (A) Some dysplastic cells show cytoplasmic expression with blurring margination for NPM. (B) Type B mutation of NPM1 with CATG insertion (GenBank Accession No. AY740635) was confirmed by sequencing. Abbreviations: See Tables 1 and 3.

  • Fig. 2. Kaplan-Meier survival curves. MDS patients with FLT3-ITD (N=5, straight line) or without FLT3-ITD (N=29, dotted line) at AML transformation. Abbreviations: See Table 1.


Reference

References

1. Hofmann WK, Lubbert M, Hoelzer D, Phillip Koeffler H. Myelodysplastic syndromes. Hematol J. 2004; 5:1–8.
Article
2. Morgan MA and Reuter CW. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol. 2006; 85:139–63.
Article
3. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993; 82:1110–9.
Article
4. Shih LY, Lin TL, Wang PN, Wu JH, Dunn P, Kuo MC, et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer. 2004; 101:989–98.
5. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004; 18:466–75.
Article
6. Yun JP, Chew EC, Liew CT, Chan JY, Jin ML, Ding MX, et al. Nucleo-phosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J Cell Biochem. 2003; 90:1140–8.
Article
7. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989; 56:379–90.
Article
8. Chan WY, Liu QR, Borjigin J, Busch H, Rennert OM, Tease LA, et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry. 1989; 28:1033–9.
Article
9. Feuerstein N, Chan PK, Mond JJ. Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem. 1988; 263:10608–12.
Article
10. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352:254–66.
Article
11. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006; 108:1999–2005.
Article
12. Cazzaniga G, Dell´Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005; 106:1419–22.
Article
13. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100:59–66.
Article
14. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005; 106:2854–61.
Article
15. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106:3740–6.
16. Falini B. Any role for the nucleophosmin (NPM1) gene in myelodys-plastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities? Leuk Lymphoma. 2007; 48:2093–5.
Article
17. Ishikawa Y, Xu J, Sakashita G, Urano T, Suzuki T, Tomita A, et al. Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes. Leuk Lymphoma. 2008; 49:2359–64.
Article
18. Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, et al. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma. 2007; 48:2141–4.
Article
19. Zhang Y, Zhang M, Yang L, Xiao Z. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res. 2007; 31:109–11.
Article
20. Swerdlow SH, Campo E, et al. eds. WHO Classification of tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon: IARC;2008.
21. Vince A, Poljak M, Seme K. DNA extraction from archival Giemsa-stained bone-marrow slides: comparison of six rapid methods. Br J Haematol. 1998; 101:349–51.
Article
22. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11:1447–52.
23. Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol. 2008; 142:489–92.
24. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–88.
Article
25. Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol. 2010; 22:646–55.
Article
26. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363:2424–33.
Article
27. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361:1058–66.
28. Steensma DP and Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006; 81:104–30.
29. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009; 114:3448–58.
Article
30. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M, et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia. 1994; 8:1331–6.
31. Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, et al. Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001; 112:148–54.
32. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997; 11:1442–6.
Article
33. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007; 92:744–52.
Article
34. Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S, et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol. 2006; 134:302–6.
Article
35. Pinheiro RF, de Sa Moreira E, Silva MR, Alberto FL, Chauffaille Mde L. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet. 2008; 183:89–93.
Article
36. Visani G, Bernasconi P, Boni M, Castoldi G, Ciolli S, Clavio M, et al. The prognostic value of cytogenetics is reinforced by the kind of in-duction/consolidation therapy in influencing the outcome of acute myeloid leukemia–analysis of 848 patients. Leukemia. 2001; 15:903–9.
37. Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martinelli G. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica. 2007; 92:1268–9.
Article
38. Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander SK, Zellmeier E, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol. 2009; 144:517–23.
39. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009; 115:4737–44.
Article
Full Text Links
  • LMO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr